- Stocks
- Pharma & Healthcare
- Venus Remedies
Venus Remedies share price
NSE: VENUSREMPharma & HealthcareDrug Manufacturers - Specialty & Generic
Venus Remedies at a glance
Venus Remedies (NSE: VENUSREM) closed at ₹1,796.10 on 30 Sep 2026. With a market capitalisation of ₹2,401 Cr, it ranks 1058th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 23.3× trailing earnings, against a return on equity of 15.5% in FY26. Over the past year the share price has risen 293.9%. Its 52-week range is ₹428.00 (30 Sep 2025) to ₹2,044.30 (29 Jun 2026); the last close is 12.1% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹179 Cr (+35.6% year on year) and net profit ₹23 Cr (+139.3%), on a consolidated basis. Promoters held 41.76% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹2,401 CrRank 1058 on NSE
- P/E (trailing)
- 23.3×
- Price to book
- 1.66×FY26
- EPS (TTM)
- ₹86.91to Q1 FY27
- ROE
- 15.5%FY26
- ROCE
- 19.4%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 13.4%FY26
- Book value / share
- ₹496.45FY26
- 52-week high
- ₹2,044.3029 Jun 2026
- 52-week low
- ₹428.0030 Sep 2025
- 1-year return
- +293.9%
- RSI (14-day)
- 64.7
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +5.00% | +9.3% | +8.2% | +2.6% | +293.9% |
Venus Remedies quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹167 Cr | ₹177 Cr | ₹195 Cr | ₹132 Cr | ₹193 Cr | ₹180 Cr | ₹259 Cr | ₹179 Cr |
| Revenue YoY | −0.2% | +23.3% | −0.1% | +21.4% | +15.1% | +1.9% | +33.0% | +35.6% |
| Net profit | ₹4 Cr | ₹20 Cr | ₹21 Cr | ₹10 Cr | ₹20 Cr | ₹26 Cr | ₹47 Cr | ₹23 Cr |
| Net profit YoY | −64.6% | +186.1% | +99.8% | +686.9% | +471.9% | +30.5% | +126.1% | +139.3% |
| Net margin | 2.1% | 11.1% | 10.8% | 7.3% | 10.4% | 14.2% | 18.3% | 12.8% |
| EPS | ₹2.63 | ₹14.66 | ₹15.71 | ₹7.18 | ₹15.06 | ₹19.14 | ₹35.53 | ₹17.18 |
Venus Remedies financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹548 Cr | ₹599 Cr | ₹556 Cr | ₹601 Cr | ₹648 Cr | — |
| Operating profit | ₹25 Cr | ₹36 Cr | ₹38 Cr | ₹45 Cr | ₹62 Cr | — |
| Net profit | ₹62 Cr | ₹41 Cr | ₹27 Cr | ₹28 Cr | ₹45 Cr | — |
| EPS (₹) | ₹50.00 | ₹31.00 | ₹20.00 | ₹21.00 | ₹34.00 | — |
| Cash from operations | ₹133 Cr | ₹41 Cr | ₹37 Cr | ₹37 Cr | ₹86 Cr | — |
| Total debt | ₹47 Cr | ₹39 Cr | ₹39 Cr | ₹39 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹400 Cr | ₹440 Cr | ₹460 Cr | ₹488 Cr | ₹561 Cr | ₹664 Cr |
Venus Remedies shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% |
| Foreign institutions | 1.34% | 2.24% | 1.86% | 2.26% | 2.80% | 2.92% |
| Domestic institutions | — | 0.11% | 0.75% | 1.03% | 1.20% | 0.89% |
| Non-institutions | 56.90% | 55.89% | 55.63% | 54.96% | 54.24% | 54.43% |
Venus Remedies vs peers
The listed Pharma & Healthcare companies nearest to Venus Remedies by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| DPC02Dishman Pharma | — | — | — | ₹2,676 Cr | — | — |
| HIKALHikal | ₹210.01 | −0.52% | −11.8% | ₹2,589 Cr | — | — |
| DRAGARWQDr Agarwals Eye Hospital | ₹5,025.00 | +0.12% | — | ₹2,428 Cr | — | — |
| VENUSREMVenus Remedies | ₹1,796.10 | +5.00% | +293.9% | ₹2,401 Cr | 23.3 | — |
| ALEMBICLTDAlembic | ₹92.33 | +0.21% | −2.9% | ₹2,371 Cr | 7.5 | — |
| FREDUNFredun Pharmace | ₹1,376.10 | −0.35% | — | ₹2,276 Cr | 22.5 | — |
| DCALDishman Carbogen Amcis | ₹141.95 | +0.07% | −49.1% | ₹2,226 Cr | 22.8 | — |
Ask anything about Venus Remedies
Pivot answers on the live chart with evidence you can check, and tests strategies against VENUSREM's own history. Try: “Why has VENUSREM moved over the last three months?” · “Backtest a 50-day moving-average crossover on VENUSREM over five years” · “Compare VENUSREM with DPC02 on margins and valuation”
Frequently asked questions about Venus Remedies
What is the share price of Venus Remedies today?
Venus Remedies (NSE: VENUSREM) last closed at ₹1,796.10 on 30 Sep 2026. Its 52-week high is ₹2,044.30 and its 52-week low is ₹428.00.
What is the market cap of Venus Remedies?
Venus Remedies' market capitalisation is ₹2,401 Cr (₹2,401 Cr) at the 22 Oct 2026 close, ranking 1058th among the NSE companies Pivot tracks.
What is the P/E ratio of Venus Remedies?
Venus Remedies trades at a trailing P/E of 23.3. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 22.5.
What is the ROE and ROCE of Venus Remedies?
Return on equity was 15.5% in FY26 and return on capital employed was 19.4% in FY26 (consolidated figures).
Is Venus Remedies a debt-free company?
Venus Remedies is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Venus Remedies' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Venus Remedies reported revenue of ₹179 Cr, +35.6% year on year, and net profit of ₹23 Cr, +139.3% year on year.
How has Venus Remedies stock performed over the last year?
Venus Remedies' share price has risen 293.9% over the past year, +2.6% over three months and +8.2% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Venus Remedies?
As of 30 Jun 2026: promoters 41.76%, foreign institutions 2.92%, domestic institutions 0.89%, non-institutions 54.43%.
Who are Venus Remedies' competitors?
The listed Pharma & Healthcare companies closest to Venus Remedies by market cap are Dishman Pharma, Hikal, Dr Agarwals Eye Hospital, Alembic, Fredun Pharmace and Dishman Carbogen Amcis.
Is Venus Remedies a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Venus Remedies' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VENUSREM against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 30 Sep 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with V · all NSE stocks · this page as text